drugset / Trial / NCT00122382

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

NCT00122382

Phase 3 Completed 1052 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.

Timeline

Start
2005-07
Primary completion
2008-02
Completion
2009-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abatacept Other / unclassified 10 mg/kg Intravenous
Comparator Methotrexate Small molecule 15 mg Oral
Comparator Methotrexate Small molecule 20 mg Oral

Indications